ubxn1 Antibody

What is UBXN1 and what are its primary functions in cellular pathways?

UBXN1 (UBX domain-containing protein 1, also known as SAKS1) is a ubiquitin-binding protein with multiple biological functions. It contains a UBA (ubiquitin-associated) domain that specifically recognizes K6-linked polyubiquitin chains and plays regulatory roles in several cellular processes:

• Innate immune response modulation: UBXN1 functions as a negative regulator of both RIG-I-like receptors (RLR) and NF-kappa-B pathways. Following viral infection, UBXN1 is induced and recruited to the RLR component MAVS, where it interferes with MAVS oligomerization and disrupts the MAVS/TRAF3/TRAF6 signalosome, serving as a brake to prevent excessive RLR signaling .

• Tumor suppressor regulation: UBXN1 interacts with the BRCA1-BARD1 heterodimer and regulates its activity by binding to autoubiquitinated BRCA1. This interaction leads to the inhibition of the E3 ubiquitin-protein ligase activity of the BRCA1-BARD1 heterodimer .

• ER proteostasis maintenance: UBXN1 plays a critical role in maintaining endoplasmic reticulum proteostasis and repressing unfolded protein response (UPR) activation. Research has shown that UBXN1 knockout cells exhibit increased levels of UPR markers like BiP, ATF4, and phosphorylated eIF2α even under basal conditions .

• Autophagy pathway involvement: UBXN1 has been implicated in autophagy-related pathways where it assists in removing damaged proteins and organelles, cooperating with signaling proteins like LC3 which are essential for autophagic vesicle formation .

What applications can UBXN1 antibodies be used for in research settings?

UBXN1 antibodies have been validated for multiple research applications, each providing different insights into protein expression, localization, and interactions:

Validation data suggests that UBXN1 antibodies can detect a protein of approximately 40-45 kDa in various human and rodent samples, including cell lines (HeLa, HepG2, SH-SY5Y) and tissues (brain, liver, heart) .

How should I validate the specificity of a UBXN1 antibody for my research?

Validating antibody specificity is crucial for reliable research results. For UBXN1 antibodies, consider implementing these validation strategies:

• Positive and negative controls:

  • Positive controls: Use cell lines or tissues known to express UBXN1 (HeLa, HepG2, mouse liver tissue)

  • Negative controls: Employ UBXN1 knockout models generated by CRISPR-Cas9 or siRNA-mediated knockdown

• Multiple detection methods: Validate findings using at least two different techniques (e.g., WB and IHC) to confirm specificity

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (40-45 kDa for human UBXN1)

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide before application to demonstrate signal specificity

• Orthogonal validation: Compare results with alternative antibodies targeting different epitopes of UBXN1

• Functional validation: Verify that experimental results align with known UBXN1 functions, such as its role in ER stress response or interaction with BRCA1

What are the optimal sample preparation protocols for detecting UBXN1?

Effective sample preparation is essential for successful detection of UBXN1:

• For Western blotting:

  • Use RIPA or NP-40 lysis buffers containing protease inhibitors

  • Include phosphatase inhibitors when studying UBXN1's role in signaling pathways

  • For detecting UBXN1 interactions with ubiquitinated proteins, include deubiquitinase inhibitors (N-ethylmaleimide or PR-619)

  • Heat samples at 95°C for 5 minutes in reducing Laemmli buffer before loading

• For immunohistochemistry:

  • Optimal fixation: 10% neutral buffered formalin

  • Recommended antigen retrieval: TE buffer pH 9.0 (alternative: citrate buffer pH 6.0)

  • Block with 5% normal serum from the same species as the secondary antibody

• For immunoprecipitation studies:

  • Use gentler lysis buffers (e.g., 1% NP-40, 150mM NaCl, 50mM Tris pH 8.0) to preserve protein-protein interactions

  • For studying UBXN1-BRCA1 interactions, consider crosslinking approaches to stabilize transient interactions

How can I effectively study UBXN1's role in modulating ER stress and the unfolded protein response?

UBXN1 has been shown to maintain ER proteostasis and repress UPR activation. To study this role effectively:

• Experimental models:

  • Compare wild-type and UBXN1 knockout cell lines generated via CRISPR-Cas9

  • Use inducible knockdown systems to study temporal effects

  • Apply ER stress inducers: dithiothreitol (DTT), thapsigargin (Tg), or tunicamycin at various concentrations and timepoints

• Key readouts to measure:

  • Monitor UPR sensor activation:

    • PERK pathway: Measure phosphorylation of eIF2α and ATF4 expression by western blot

    • IRE1α pathway: Quantify XBP1 splicing by RT-PCR using primers spanning the splice site

    • ATF6 pathway: Detect cleaved ATF6 (co-treatment with proteasome inhibitor Bortezomib helps visualize the N-terminus)

  • Assess RIDD activity by measuring decay of known target mRNAs (bloc1s1, cd59) via qRT-PCR

  • Evaluate global transcriptional changes through RNA-seq or microarray analysis

• Data analysis approaches:

  • Compare response kinetics and magnitude between wild-type and UBXN1 KO cells

  • Perform hierarchical clustering analysis of gene expression patterns

  • Consider ceiling effects in UPR target gene expression when interpreting data

• Complementary strategies:

  • Rescue experiments with wild-type UBXN1 or domain mutants

  • Proximity labeling methods (BioID, APEX) to identify UBXN1 interaction partners during ER stress

What are the best methods to investigate UBXN1's interaction with BRCA1 and its effects on ubiquitination?

UBXN1 specifically binds 'Lys-6'-linked polyubiquitin chains and interacts with autoubiquitinated BRCA1, inhibiting the E3 ligase activity of the BRCA1-BARD1 heterodimer . To study this interaction:

• Protein interaction studies:

  • Co-immunoprecipitation with antibodies against UBXN1 or BRCA1/BARD1

  • Domain mapping using truncated proteins to identify interaction interfaces

  • GST pull-down assays with recombinant proteins

• Ubiquitination analysis:

  • In vitro ubiquitination assays using purified components (BRCA1/BARD1, E1, UbcH5c, ubiquitin)

  • Use of ubiquitin mutants (e.g., K6-only, K6R) to study linkage specificity

  • Tandem ubiquitin binding entities (TUBEs) to capture specific ubiquitin chain types

• Structural approaches:

  • Analysis of the UBA domain of UBXN1 binding to K6-linked polyubiquitin chains

  • Investigation of how C-terminal sequences of UBXN1 interact with BRCA1/BARD1 in a ubiquitin-independent manner

• Functional assays:

  • DNA damage response assessment in cells with modulated UBXN1 levels

  • Cell cycle analysis to determine if UBXN1-BRCA1 interaction affects cell proliferation

  • BRCA1 substrate ubiquitination in the presence or absence of UBXN1

How can I optimize experimental design to investigate UBXN1's role in innate immune responses?

UBXN1 functions as a negative regulator of innate immune signaling pathways. To study this role effectively:

• Experimental setup:

  • Cell models: Use immune cell lines or primary cells with UBXN1 knockout or overexpression

  • Stimulation conditions: Viral infection or pathway-specific stimuli (e.g., poly(I:C) for RLR pathway, TNFα for NF-κB pathway)

  • Time-course experiments to capture dynamic responses

• Key pathways to examine:

  • RIG-I-like receptor pathway:

    • Monitor MAVS oligomerization and MAVS/TRAF3/TRAF6 signalosome formation

    • Measure downstream signaling events (IRF3 phosphorylation, type I interferon production)

  • NF-κB pathway:

    • Assess interaction with cellular inhibitors of apoptosis proteins (cIAPs)

    • Monitor IκBα degradation and NF-κB nuclear translocation

    • Measure NF-κB-dependent gene expression

• Advanced techniques:

  • Proximity ligation assay to detect protein-protein interactions in situ

  • ChIP-seq to examine changes in transcription factor binding to chromatin

  • Single-cell analysis to capture cell-to-cell variability in immune responses

• Integrated data analysis:

  • Network analysis to understand pathway interconnections

  • Mathematical modeling of signaling dynamics in the presence/absence of UBXN1

  • Correlation of UBXN1 expression with immune response outcomes

What approaches should be used to address experimental variability when working with UBXN1 antibodies?

Working with antibodies can introduce various sources of variability. For UBXN1 research:

• Antibody selection and validation:

  • Compare multiple commercially available antibodies (e.g., Proteintech 16135-1-AP, Cell Signaling E5B5J) for your specific application

  • Validate each lot with appropriate positive and negative controls

  • Consider recombinant antibodies for higher lot-to-lot consistency

• Protocol standardization:

  • Optimize antibody concentration for each application and cell/tissue type

  • Standardize sample preparation, including lysis buffers and protein quantification

  • Include internal loading controls and normalization standards

• Technical considerations:

  • For Western blotting:

    • Expected molecular weight: 40-45 kDa

    • Recommended dilutions: 1:5000-1:30000 (antibody-dependent)

  • For immunohistochemistry:

    • Appropriate antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

    • Recommended dilutions: 1:500-1:2000

• Addressing conflicting results:

  • When different antibodies yield inconsistent results:

    • Verify epitope locations to ensure they target different regions of UBXN1

    • Consider post-translational modifications that might affect epitope recognition

    • Use orthogonal methods (e.g., mass spectrometry) for validation

How can CRISPR-Cas9 generated UBXN1 knockout models be effectively validated and utilized?

CRISPR-Cas9 knockout models provide powerful tools for studying UBXN1 function, but require proper validation:

• Validation strategies:

  • Genomic validation: Sequencing to confirm indels at the target site

  • Transcript validation: RT-PCR and qPCR to verify absence of UBXN1 mRNA

  • Protein validation: Western blot using antibodies targeting different epitopes of UBXN1

  • Functional validation: Assess established UBXN1-dependent phenotypes (e.g., elevated UPR markers)

• Experimental considerations:

  • Generate multiple independent knockout clones to control for off-target effects

  • Include appropriate rescue experiments with wild-type UBXN1 or mutant variants

  • Consider cell type-specific effects when interpreting results

• Phenotypic characterization:

  • Baseline characterization:

    • Gene expression profiling reveals that untreated UBXN1 KO cells show expression patterns resembling stressed wild-type cells

    • Monitor UPR markers (BiP, ATF4, phospho-eIF2α, XBP1 splicing) under basal conditions

  • Stress response assessment:

    • Compare response to ER stressors (e.g., DTT, thapsigargin)

    • Examine viral infection responses

    • Assess DNA damage responses due to UBXN1's connection to BRCA1

• Advanced applications:

  • Generate domain-specific mutants rather than complete knockouts to dissect function

  • Create knockin cell lines expressing tagged versions of UBXN1 for interaction studies

  • Use inducible CRISPR systems for temporal control of UBXN1 depletion

How should I interpret conflicting results when studying UBXN1's multiple cellular functions?

UBXN1 participates in diverse cellular processes, which can lead to complex or seemingly contradictory experimental outcomes:

• Context-dependent functions:

  • Cell type specificity: UBXN1's role may vary between immune cells, cancer cells, and other specialized cells

  • Subcellular localization: Consider compartment-specific functions when interpreting results

  • Protein levels: Effects may differ between knockdown (partial depletion) and knockout (complete absence)

• Interconnected pathways:

  • UBXN1 affects both ER stress and innate immune signaling, which are interconnected

  • When studying one pathway, assess potential indirect effects via other UBXN1-regulated processes

  • Use pathway-specific inhibitors to isolate contributions

• Data integration strategies:

  • Multi-omics approach: Combine proteomics, transcriptomics, and functional assays

  • Temporal analysis: Map the sequence of events following UBXN1 perturbation

  • Dose-dependent effects: Titrate expression levels to identify thresholds for different functions

• Addressing contradictory findings:

  • Examine experimental conditions (cell density, passage number, media components)

  • Consider post-translational modifications affecting UBXN1 function

  • Assess for potential compensatory mechanisms in chronic knockout models

What are the critical considerations when using UBXN1 antibodies for protein interaction studies?

Studying UBXN1's interactions requires careful experimental design:

• Lysis conditions:

  • Optimize buffer composition: Stringent buffers may disrupt weak interactions

  • Consider crosslinking approaches for transient interactions

  • Include appropriate inhibitors to preserve ubiquitination states

• Co-immunoprecipitation optimization:

  • Antibody selection: Choose antibodies that don't interfere with interaction interfaces

  • Control for antibody specificity: Include IgG controls and UBXN1 knockout samples

  • Validation with reciprocal IPs: Confirm interactions by pulling down with antibodies against both interaction partners

• Detecting specific interactions:

  • UBXN1-BRCA1 interaction: This involves both ubiquitin-dependent binding via the UBA domain and direct protein-protein interaction via C-terminal sequences

  • UBXN1-MAVS interaction: Consider using stimulation conditions (viral infection) to enhance this interaction

  • UBXN1-CUL1 interaction: Important for understanding UBXN1's role in NF-κB inhibition

• Advanced approaches:

  • Proximity labeling (BioID, APEX) to identify interaction partners in living cells

  • FRET or BiFC to visualize interactions in real-time

  • Domain mapping using truncation mutants to identify interaction interfaces

What emerging techniques show promise for advancing UBXN1 research?

Several cutting-edge approaches could significantly enhance our understanding of UBXN1 biology:

• Structural biology approaches:

  • Cryo-EM structures of UBXN1 in complex with binding partners

  • Hydrogen-deuterium exchange mass spectrometry to map interaction surfaces

  • Single-molecule techniques to study dynamic conformational changes

• Advanced genetic tools:

  • Base editing or prime editing for precise modification of UBXN1 domains

  • Conditional knockout models to study tissue-specific functions

  • CRISPR screens to identify genetic interactions with UBXN1

• Imaging innovations:

  • Super-resolution microscopy to visualize UBXN1 subcellular localization

  • Live-cell imaging with fluorescent UBXN1 fusions to track dynamics

  • Correlative light and electron microscopy to study UBXN1 in the context of cellular ultrastructure

• Systems biology integration:

  • Multi-omics profiling in UBXN1 models under various stress conditions

  • Network analysis to position UBXN1 within cellular signaling maps

  • Mathematical modeling of UBXN1's role in ER homeostasis and immune response

How might UBXN1 research contribute to understanding disease mechanisms?

UBXN1's diverse functions suggest potential roles in multiple disease processes:

• Cancer biology:

  • UBXN1's interaction with BRCA1-BARD1 may influence DNA repair and genomic stability

  • Potential roles in modulating tumor cell responses to ER stress

  • Possible impact on anti-tumor immune responses through innate immune pathway regulation

• Inflammatory disorders:

  • As a negative regulator of NF-κB and RLR pathways, UBXN1 may influence inflammatory disease progression

  • Potential therapeutic target for conditions with excessive immune activation

  • Role in preventing inappropriate activation of innate immunity

• Neurodegenerative diseases:

  • UBXN1's role in ER proteostasis may be relevant to protein misfolding disorders

  • Potential contributor to neuroinflammatory aspects of neurodegeneration

  • Involvement in autophagy might affect protein aggregate clearance

• Viral infections:

  • UBXN1 modulates antiviral signaling pathways and may influence infection outcomes

  • Some viruses might target UBXN1 to evade immune responses

  • UBXN1 interacts with the S1 protein of transmissible gastroenteritis coronavirus and plays a role in viral replication